In vivo-stable bis-iminobiotin for targeted radionuclide delivery with the mutant streptavidin

Toshifumi Tatsumi,Songji Zhao,Akitomo Kasahara,Miho Aoki,Ken-ichi Nishijima,Naoyuki Ukon,Tatsuhiko Kodama,Kazuhiro Takahashi,Akira Sugiyama,Kohshin Washiyama,Kenzo Yamatsugu,Motomu Kanai

DOI: https://doi.org/10.1016/j.bmcl.2024.129803

IF: 2.94

2024-05-22

Bioorganic & Medicinal Chemistry Letters

Abstract:Targeted delivery of radionuclides to tumors is significant in theranostics applications for precision medicine. Pre-targeting, in which a tumor-targeting vehicle and a radionuclide-loaded effector small molecule are administered separately, holds promise since it can reduce unnecessary internal radiation exposure of healthy cells and can minimize radiation decay. The success of the pre-targeting delivery requires an in vivo -stable tumor-targeting vehicle selectively binding to tumor antigens and an in vivo -stable small molecule effector selectively binding to the vehicle accumulated on the tumor. We previously reported a drug delivery system composed of a low-immunogenic streptavidin with weakened affinity to endogenous biotin and a bis-iminobiotin with high affinity to the engineered streptavidin. It was, however, unknown whether the bis-iminobiotin is stable in vivo when administered alone for the pre-targeting applications. Here we report a new in vivo -stable bis-iminobiotin derivative. The keys to success were the identification of the degradation site of the original bis-iminobiotin treated with mouse plasma and the structural modification of the degradation site. We disclosed the successful pre-targeting delivery of astatine-221 ( 211 At), α-particle emitter, to the CEACAM5-positive tumor in xenograft mouse models.

chemistry, medicinal, organic